Radzikowska Joanna, Czarnecka Anna M, Klepacka Teresa, Rychłowska-Pruszyńska Magdalena, Raciborska Anna, Dembowska-Bagińska Bożenna, Pronicki Maciej, Kukwa Andrzej, Fendler Wojciech, Smyczyńska Urszula, Kukwa Wojciech, Krzeski Antoni
Department of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Stepinska 19/25, 00-739 Warsaw, Poland.
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
Diagnostics (Basel). 2022 Aug 4;12(8):1895. doi: 10.3390/diagnostics12081895.
(1) Background: The aim of the present study was to assess the cancer stem cell (CSC) markers CD24, CD44, CD133, and ALDH1A1 in rhabdomyosarcoma (RMS) in children and to define their prognostic role in this group of patients. (2) Methods: The study material was archival tissue specimens collected from 49 patients under 18 years of age and who had been diagnosed with RMS. Immunohistochemistry (IHC) was used to evaluate the expression of the selected CSC markers in the tumor tissue. Expression was evaluated using a semiquantitative IRS scale based on the one developed by Remmele and Stenger and was correlated with the clinical and pathomorphological parameters of prognostic importance in RMS. (3) Results: Expression of the selected CSC markers CD24, CD44, CD133, and ALDH1A1 was demonstrated in 83.7%, 55.1%, 81.6%, and 100% of the RMS patients, respectively. The expression of all of the assessed CSC markers was statistically significantly higher in the study group versus the control group. No significant correlation was found between the expression of the selected CSC markers and clinical and pathological prognostic factors that were analyzed. The expression of the CSC markers did not have a significant influence on RMS survival rates. (4) Conclusions: The results of the conducted study confirm the expression of selected CSC markers in rhabdomyosarcoma tissue in children. The study did not support the prognostic relevance of the expression of any of the assessed CSC markers. However, further studies are needed to fully understand the relevance of the selected CSC markers in RMS carcinogenesis.
(1) 背景：本研究旨在评估儿童横纹肌肉瘤（RMS）中癌症干细胞（CSC）标志物CD24、CD44、CD133和醛脱氢酶1A1（ALDH1A1），并确定它们在这组患者中的预后作用。(2) 方法：研究材料为从49例18岁以下被诊断为RMS的患者身上采集的存档组织标本。免疫组织化学（IHC）用于评估肿瘤组织中所选CSC标志物的表达。根据Remmele和Stenger开发的量表，使用半定量免疫反应评分系统（IRS）评估表达情况，并将其与RMS中具有预后重要性的临床和病理形态学参数相关联。(3) 结果：所选CSC标志物CD24、CD44、CD133和ALDH1A1在RMS患者中的表达率分别为83.7%、55.1%、81.6%和100%。研究组中所有评估的CSC标志物的表达在统计学上均显著高于对照组。所选CSC标志物的表达与所分析的临床和病理预后因素之间未发现显著相关性。CSC标志物的表达对RMS生存率没有显著影响。(4) 结论：本研究结果证实了所选CSC标志物在儿童横纹肌肉瘤组织中的表达。该研究不支持所评估的任何CSC标志物表达的预后相关性。然而，需要进一步研究以充分了解所选CSC标志物在RMS致癌过程中的相关性。
